


EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1722	((544/323) or (514/275)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/09/25 11:50



National Library of Medicine NLM



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search for

Limits Preview/Index History Clipboard Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Search	Most Recent Queries	Time	Result
	#3 Search #1 and #2	11:54:53	11
	#2 Search stimulating neuronal function	11:54:40	1359
	#1 Search pyrimidine	11:53:45	137453

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 14 2005 04:34:46



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals B
Search for #1 and #2

Limits Preview/Index History Clipboard Details

Display Summary

Show

20

Sort by

Send to

All: 11 Review: 0

Items 1 - 11 of 11

One page.

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Petroff BK, Croutch CR, Hunter DM, Wierman ME, Gao X.](#)

Related Articles, Links

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates gonadotropin secretion in the immature female Sprague-Dawley rat through a pentobarbital- and estradiol-sensitive mechanism but does not alter gonadotropin-releasing hormone (GnRH) secretion by immortalized GnRH neurons in vitro.
Biol Reprod. 2003 Jun;68(6):2100-6. Epub 2003 Jan 22.
PMID: 12606454 [PubMed - indexed for MEDLINE]

2: [Klementiev B, Bichevaja N, Novikova T, Chebotar N, Bock E, Berezin V.](#)

Related Articles, Links

A peptide agonist of the neural cell adhesion molecule (NCAM), C3, protects against developmental defects induced by a teratogen pyrimethamine.
Int J Dev Neurosci. 2002 Nov;20(7):527-36.
PMID: 12485621 [PubMed - indexed for MEDLINE]

3: [Mignon L, Wolf WA.](#)

Related Articles, Links

Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
Psychopharmacology (Berl). 2002 Aug;163(1):85-94. Epub 2002 Jul 13.
PMID: 12185404 [PubMed - indexed for MEDLINE]

4: [Spencer JP, Whiteman M, Jenner P, Halliwell B.](#)

Related Articles, Links

5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons.
J Neurochem. 2002 Apr;81(1):122-9.
PMID: 12067224 [PubMed - indexed for MEDLINE]

5: [Fiorica-Howells E, Maroteaux L, Gershon MD.](#)

Related Articles, Links

Serotonin and the 5-HT(2B) receptor in the development of enteric neurons.
J Neurosci. 2000 Jan 1;20(1):294-305.
PMID: 10627607 [PubMed - indexed for MEDLINE]

6: [Markianos M, Hatzimanolis J, Lykouras L.](#)

Related Articles, Links

Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.
Psychopharmacology (Berl). 1999 Apr;143(3):270-2.
PMID: 10353429 [PubMed - indexed for MEDLINE]

7: [Lochhead KM, Zager RA.](#)

[Related Articles](#), [Links](#)

 Fluorinated anesthetic exposure "activates" the renal cortical sphingomyelinase cascade.

Kidney Int. 1998 Aug;54(2):373-81.

PMID: 9690203 [PubMed - indexed for MEDLINE]

8: [Xu F, Frazier DT.](#)

[Related Articles](#), [Links](#)

 Medullary respiratory neuronal activity modulated by stimulation of the fastigial nucleus of the cerebellum.

Brain Res. 1995 Dec 24;705(1-2):53-64.

PMID: 8821733 [PubMed - indexed for MEDLINE]

9: [De Gennaro Colonna V, Bertola G, Coco CB, Bifano M, Cocchi D, Maggi A, Muller EE.](#)

[Related Articles](#), [Links](#)

 Changes in the hypothalamic-pituitary somatotropic function of infant hypothyroid rats.

Proc Soc Exp Biol Med. 1990 Mar;193(3):214-9.

PMID: 1968255 [PubMed - indexed for MEDLINE]

10: [Gottesfeld Z, Butler IJ, Findley WE.](#)

[Related Articles](#), [Links](#)

 Prenatal and postnatal hypothyroidism abolishes lesion-induced noradrenergic sprouting in the adult rat.

J Neurosci Res. 1985;14(1):61-9.

PMID: 4020898 [PubMed - indexed for MEDLINE]

11: [Gotz D, Ziesch C, Wenzel M, Grosse G, Schuster T, Wenzel J.](#)

[Related Articles](#), [Links](#)

 [Electron microscopic and morphometric studies on the in vitro differentiation of mitochondria in neurons of hippocampus explant cultures as affected by orotic acid and sodium orotate]

Z Mikrosk Anat Forsch. 1982;96(4):613-32. German.

PMID: 6184903 [PubMed - indexed for MEDLINE]

Display

[Summary](#)



Show

20



Sort by



Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)



[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 14 2005 04:34:46

10648046

C:\STNEXP4\QUERIES\09907273 (subgenus).str



chain nodes :

7 8 9 10 12 16

ring nodes :

1 2 3 4 5 6

chain bonds :

2-16 6-7 7-8 8-9 9-10 9-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-16 6-7 7-8 9-10 9-12

exact bonds :

8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:CLASS 16:CLASS

10/643,046
09907,273 (subgenus around elected species)

=>
Uploading 09907273.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 18:19:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5610 TO ITERATE

17.8% PROCESSED 1000 ITERATIONS 21 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 107712 TO 116688
PROJECTED ANSWERS: 1705 TO 3007

L2 21 SEA SSS SAM L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L3 SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09907273.str

L4 STRUCTURE UPLOADED

=> que L4 NOT L3

L5 QUE L4 NOT L3

=> d 15


10/648,046

~~09907273~~ (subgenus around elected species)

L5 HAS NO ANSWERS

L3 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L4 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

L5 QUE L4 NOT L3

=> s 15 sss sam

SAMPLE SEARCH INITIATED 18:25:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 446 TO ITERATE

100.0% PROCESSED 446 ITERATIONS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 7653 TO 10187

PROJECTED ANSWERS: 964 TO 1996

L6 50 SEA SSS SAM L4 NOT L3

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L7 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09907273 (subgenus).str

L8 STRUCTURE UPLOADED

=> que L8 NOT L7

L9 QUE L8 NOT L7


10/648,046
~~09/007,273~~ (subgenus around elected species)

=> d 19

L9 HAS NO ANSWERS

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L8 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.
L9 QUE L8 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 18:27:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 368 TO ITERATE

100.0% PROCESSED 368 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 6210 TO 8510

PROJECTED ANSWERS: 964 TO 1996

L10 50 SEA SSS SAM L8 NOT L7

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L11 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09907273 (subgenus).str

L12 STRUCTURE UPLOADED

=> que L12 NOT L11

L13 QUE L12 NOT L11


10/648,046
~~09/907,273~~ (subgenus around elected species)

=> d 113

L13 HAS NO ANSWERS

L11 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L12 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

L13 QUE L12 NOT L11

=> s 113 sss sam

SAMPLE SEARCH INITIATED 18:28:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 47 TO ITERATE

100.0% PROCESSED 47 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 529 TO 1351

PROJECTED ANSWERS: 3 TO 163

L14 3 SEA SSS SAM L12 NOT L11

=> s 113 sss ful

FULL SEARCH INITIATED 18:30:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1276 TO ITERATE

100.0% PROCESSED 1276 ITERATIONS

88 ANSWERS

SEARCH TIME: 00.00.01

L15 88 SEA SSS FUL L12 NOT L11

=> s 115

L16 40 L15

=> d 116 1-40 bib,ab,hitstr

L16 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:76625 CAPLUS
 DN 138:122653
 TI Pyrimidine derivatives for treatment of neurodegenerative diseases
 IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.
 PA Neotherapeutics, Inc., USA
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Applicant's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003007963	A1	20030130	WO 2002-US23246	20020717
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-907273 A 20010717 ← *Applicant's*

AB A pyrimidine deriv. or analog comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker -L-C(O)- to a moiety B, where C(O)-B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including H or alkyl, and D is a moiety that enhances the pharmacol. effects, promotes absorption, or promotes blood-brain barrier penetration of the deriv. or analog. The moiety A can have two or three N atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two N atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biol. or physiol. activity. All cited compds. (e.g. 4-[[3-[(2-amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid Et ester) have nootropic or antiamnestic activity at doses of 10 mg/kg i.p. or less. Although the methods of prepn. are not claimed, 3 example preps. are included.


IT 389799-47-7P, 4-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic Acid Ethyl Ester 389799-50-2P, 4-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid 389799-54-6P, 3-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid ethyl ester 389799-57-9P, 3-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; pyrimidine derivs. for treatment of neurodegenerative diseases)


RN 389799-47-7 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


10/648,046
~~004987-273~~ (subgenus around elected species)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



selected species

RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/648,046

~~007907,273~~ (subgenus around elected species)

L16 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:215776 CAPLUS

DN 137:70674

TI Amino-substituted 06-benzyl-5-nitrosopyrimidines: interplay of molecular, molecular-electronic and supramolecular structures

AU Quesada, Antonio; Marchal, Antonio; Melguizo, Manuel; Nogueras, Manuel; Sanchez, Adolfo; Low, John N.; Cannon, Debbie; Farrell, Dorcas M. M.; Glidewell, Christopher

CS Departamento de Quimica Inorganica y Organica, Universidad de Jaen, Jaen, 23071, Spain

SO Acta Crystallographica, Section B: Structural Science (2002), B58 (2), 300-315

CODEN: ASBSDK; ISSN: 0108-7681

PB Blackwell Munksgaard

DT Journal

LA English

AB The structures of eight 2,4,6-trisubstituted-5-nitrosopyrimidines (one of which crystallizes in two polymorphs) were detd., including seven 06-benzyl derivs. which are potential, or proven, *in vitro* inhibitors of the human DNA-repair protein 06-alkylguanine-DNA-transferase. In the derivs. having an amino substituent at the 4-position, an intramol. N-H...O H bond with the nitroso O as an acceptor leads to an overall mol. shape similar to that of substituted purines. There is a marked propensity for these nitroso compds. to crystallize with $Z' = 2$. The structure of an analog with no nitroso group is also reported for comparative purposes. Compds. contg. the N-alkyl substituents -NHCH₂COOEt, -NHCH₂CH₂COOEt and -NHCH(CH₂Ph)COOEt, derived from amino acid esters, exhibit a rich variety of conformational behavior, and in all of the nitroso compds. the bond lengths provide strong evidence for a highly polarized electronic structure. Assocd. with this polarization is extensive charge-assisted H bonding between the mols., leading to supramol. aggregation as finite (zero-dimensional) aggregates, chains, mol. ladders, sheets and frameworks.


IT 439666-61-2 439666-62-3 439666-63-4

RL: PRP (Properties)

(crystal structure of)

RN 439666-61-2 CAPLUS

CN Glycine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 439666-62-3 CAPLUS

CN .beta.-Alanine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/648,046

09/907,273 (subgenus around elected species)




Y

RN 439666-63-4 CAPLUS

CN L-Phenylalanine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Y

RE.CNT 25

THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:51464 CAPLUS
 DN 136:112673
 TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions
 IN Diamond, Jack; Glasky, Alvin J.
 PA Neotherapeutics, Inc., USA
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002055506	A1	20020509	US 2001-900844	20010706 <i>— AU 1617</i>
	US 2002061899	A1	20020523	US 2001-899901	20010706 <i>— AU 1614</i>
PRAI	US 2000-216844P	P	20000707		
OS	MARPAT	136:112673			
AB	A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.				
IT	389799-47-7 389799-50-2 389799-54-6 389799-57-9				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of disease-induced peripheral neuropathy and related conditions)				
RN	389799-47-7 CAPLUS				
CN	Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)				




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51463 CAPLUS

DN 136:112672

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 59 pp.


CODEN: PIIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004451	A2	20020117	WO 2001-US21385	20010706
	WO 2002004451	A3	20030103		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 2002040032	A1	20020404	US 2001-899478	20010705 ← E. Abn. (1614)
PRAI	US 2000-216808P	P	20000707		
OS	MARPAT	136:112672			
AB	A method of increasing the synthesis and/or secretion of synaptophysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. of analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.				
IT	389799-47-7	389799-50-2	389799-54-6		
	389799-57-9				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for stimulation of synthesis of synaptophysin in CNS)				
RN	389799-47-7	CAPLUS			
CN	Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)				




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51462 CAPLUS

DN 136:112671

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid .beta. peptide in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. : DATE

PI WO 2002004450 A2 20020117 WO 2001-US21384 20010706

WO 2002004450 A3 20021212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002040031 A1 20020404 US 2001-899611 20010705 — 1614.

PRAI US 2000-216845P P 20000707

OS MARPAT 136:112671

AB A method of either inhibiting the formation of A.beta. or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

IT 389799-47-7 389799-50-2 389799-54-6


389799-57-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for prevention of accumulation of amyloid .beta. peptide in CNS)


RN 389799-47-7 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:51461 CAPLUS
 DN 136:112691
 TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters
 IN Taylor, Eve M.
 PA Neotherapeutics, Inc., USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004449	A2	20020117	WO 2001-US21383	20010706
	WO 2002004449	A3	20020613		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002128264	A1	20020912	US 2001-900297	20010706 <i>← E. Abn. (1617)</i>
	US 2000-216616P	P	20000707		
OS	MARPAT	136:112691			
AB	One aspect of the invention is a method of treating a condition or disease assocd. with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease assocd. with the activity of a multidrug transporter protein an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine deriv. is N-4-carboxyphenyl-3-(6-oxohdropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer, a microbial or parasitic infection, HIV, infection, or a condition assocd. with inflammation, e.g. asthma or rheumatic disease.				
IT	389799-47-7	389799-50-2	389799-54-6		
	389799-57-9				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(purine deriv., pyrimidine deriv. or tetrahydroindolone deriv. for treatment of conditions affected by activity of multidrug transporters)				
RN	389799-47-7	CAPLUS			
CN	Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)				




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS


CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:51460 CAPLUS
 DN 136:112670
 TI Methods using purine derivatives, pyrimidine derivatives, and tetrahydroindolone derivatives for treatment of drug-induced peripheral neuropathy and related conditions
 IN Diamond, Jack; Glasky, Alvin J.
 PA Neotherapeutics, Inc., USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2


Search as
#3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002055506	A1	20020509	US 2001-900844	20010706 ✓
	US 2002061899	A1	20020523	US 2001-899901	20010706 ✓
PRAI	US 2000-216844P	P	20000707		
OS	MARPAT	136:112670			
AB	A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy assocd. with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy assocd. with the administration of vincristine, paclitaxel, or cisplatin.				
IT	389799-47-7	389799-50-2	389799-54-6		
	389799-57-9				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of drug-induced peripheral neuropathy and related conditions)				
RN	389799-47-7	CAPLUS			
CN	Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)				




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[(3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:345113 CAPLUS
 DN 135:12332
 TI N-(2-Amino-1,6-dihydro-5-nitroso-6-oxopyrimidin-4-yl)-L-isoleucine-water(4/1): interplay of molecular and supramolecular structures
 AU Low, John N.; Cannon, Debbie; Quesada, Antonio; Marchal, Antonio; Melguizo, Manuel; Nogueras, Manuel; Sanchez, Adolfo; Glidewell, Christopher
 CS Department of Chemistry, University of Aberdeen, Meston Walk, Old Aberdeen, AB24 3UE, UK
 SO Acta Crystallographica, Section C: Crystal Structure Communications (2001), C57(5), 604-607
 CODEN: ACSCEE; ISSN: 0108-2701
 PB Munksgaard International Publishers Ltd.
 DT Journal
 LA English
 AB In the title compd., $2\text{C}10\text{H}15\text{N}5\text{O}4\text{.cntdot.}0.5\text{H}_2\text{O}$, there are two independent mols. of the pyrimidinylisoleucine in general positions and a H_2O mol. lying on a 2-fold rotation axis. The bond lengths within the org. moieties demonstrate significant polarization of the electronic structure. Each of the org. mols. participates in 12 intermol. H bonds, of $\text{O}-\text{H}\dots\text{O}$ and $\text{N}-\text{H}\dots\text{O}$ types, while the H_2O mol. acts as a double donor and as a double acceptor of $\text{O}-\text{H}\dots\text{O}$ H bonds. The org. components are linked by the H bonds into a single three-dimensional framework, reinforced by the H_2O mols. Crystallog. data are given.
 IT 340993-79-5
 RL: PRP (Properties)
 (prepn. and crystal structure)
 RN 340993-79-5 CAPLUS
 CN L-Isoleucine, N-(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)-, hydrate (4:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 1/4 H_2O

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:84798 CAPLUS
 DN 132:137383
 TI Preparation of pyrazole derivatives as antitumor agents
 IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki; Makino, Chie
 PA Daiichi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 189 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005230	A1	20000203	WO 1999-JP3962	19990723
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9948002	A1	20000214	AU 1999-48002	19990723
	EP 1103551	A1	20010530	EP 1999-931515	19990723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000169475	A2	20000620	JP 1999-211211	19990726
	NO 2001000405	A	20010322	NO 2001-405	20010123
PRAI	JP 1998-208807	A	19980724		
	JP 1998-274459	A	19980929		
	WO 1999-JP3962	W	19990723		
OS	MARPAT	132:137383			
AB	The title compds. I [R1 = H, halo, etc.; R2 = H, halo, OH, etc.; R3 = H, amino, alkoxy, etc.; R4 = H, halo, alkylamino, etc.; R5 = H, alkyl, etc.; Q = heterocyclic ring, etc.; G = heterocyclic ring (further details on said ring are given)] are prep'd. Compds. of this invention in vitro showed IC50 values of 0.6 ng/mL to 35 ng/mL against the growth of lung tumor cells.				
IT	256929-34-7P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of pyrazole derivs. as antitumor agents)				
RN	256929-34-7	CAPLUS			
CN	Glycine, N-[2-amino-6-[4-[(1E)-3-[4-(3,5-difluorophenyl)-1-piperazinyl]-1-propenyl]-5-methyl-1H-pyrazol-1-yl]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)				


Double bond geometry as shown.



L16 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:435156 CAPLUS
 DN 121:35156
 TI Cyclodehydration of 5-[(Carboxymethyl)amino]pyrimidines. Synthesis and Characterization of Novel Mesoionic Imidazo[1,2-c]pyrimidin-3-ones
 AU Edstrom, Eric D.; Wei, Yuan; Gordon, Michelle
 CS Department of Chemistry and Biochemistry, Utah State University, Logan, UT, 84322-0300, USA
 SO Journal of Organic Chemistry (1994), 59(9), 2473-81
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 AB The cyclodehydration of 5-(carboxymethyl)amino-substituted pyrimidines I (R1 = SMe, NH2) using acid anhydrides provided a general prepn. of novel mesoionic imidazo[1,2-c]pyrimidin-3-one compds., for example II (same R1). Compds. lacking a blocking group at N-1 undergo clean alkylation at this position, under basic reaction conditions, with substituted alkyl chlorides. Imidazo[1,2-c]pyrimidin-3-ones having a benzyl group at N-1 were found to undergo substitution reactions on the pyrimidine ring in the presence of basic nucleophiles. Thus, replacement of a 5-methylthio over a 7-chloro substituent was favored, whereas the 7-chloro group was substituted in compds. where a 5-amino substituent was present. Exposure of imidazo[1,2-c]pyrimidin-3-ones to aq. acid results in the ring opening of the 5-membered ring with loss of CO2 in an overall net reversion of the cyclodehydration reaction. Examm. of the x-ray structures obtained for some II indicated that the 5-membered ring was not arom., but rather a combination of a ring-opened valence tautomer and a charge-delocalized resonance hybrid structure.
 IT 155670-18-1P 155670-23-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate for imidazo[1,2-c]pyrimidinone resonance hybrid)
 RN 155670-18-1 CAPLUS
 CN Glycine, N-(2-amino-6-chloro-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 155670-23-8 CAPLUS
 CN Glycine, N-(2-amino-6-chloro-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L16 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1993:234397 CAPLUS

DN 118:234397

TI Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase

AU Chern, Ji Wang; Lee, Horng Yuh; Chen, Chien Shu; Shewach, Donna S.; Daddona, Peter E.; Townsend, Leroy B.

CS Med. Lab., Natl. Def. Med. Cent., Taipei, 100, Taiwan

SO Journal of Medicinal Chemistry (1993), 36(8), 1024-31

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


AB In an effort to develop potent human purine nucleoside phosphorylase (PNP) inhibitors as immunosuppressive and chemotherapeutic agents, several 8-aminoguanine derivs., e.g. I [R = (CH₂)₅Me, (CH₂)₅CO₂H, R₁-R₃, R₄ = OH, SPh (II), R₅ = iodo, COC₆H₄SO₂F-4], and formycin derivs. III (R₆ = SPh, COC₆H₄SO₂F-4), were synthesized and evaluated as potential PNP inhibitors. These studies were designed to investigate the hydrophobic effect of a substituent on the N-9 of the purine heterocycle and/or the C-5' positions. The affinity of these compds. to erythrocytic PNP was detd. and none of these compds. showed a better affinity than those of the parent compds. The effect of hydrophobicity at the N-9 and the C-5' positions might play an important role in binding to the active site of PNP. Thus, compd. II was found to be the best inhibitor in this series.

IT 146203-16-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and ring closure of)

RN 146203-16-9 CAPLUS

CN Hexanoic acid, 6-[[2-amino-1,6-dihydro-5-[[[(methoxycarbonyl)amino]thioxomethyl]amino]-6-oxo-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:675113 CAPLUS
 DN 115:275113
 TI A novel theory of tripartate conjugate and its application to synthesize soluble macromolecular conjugates
 AU Bhattacharyya, A.
 CS Div. Biochem. Eng., Indian Inst. Chem. Biol., Calcutta, 700 032, India
 SO Journal of the Indian Chemical Society (1991), 68(3), 172-4
 CODEN: JICSAH; ISSN: 0019-4522
 DT Journal
 LA English
 AB A scheme was designed by which a tripartite conjugate can be constructed. The conjugate is designed as a ligand-bridge-protein. The insol. org. compd. (ligand) is coupled to a macromol. (protein) via a very hydrophilic water-sol. mol. (bridge). It was found that citric acid can be an effective bridge.
 IT 137682-09-8P
 RL: PREP (Preparation)
 (prepn. and conjugation with albumin)
 RN 137682-09-8 CAPLUS
 CN Butanedioic acid, 2-[2-[[2-amino-5-(4-chlorophenyl)-6-ethyl-4-pyrimidinyl]amino]-2-oxoethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



8

IT 137682-09-8DP, albumin conjugates
 RL: PREP (Preparation)
 (prepn. of)
 RN 137682-09-8 CAPLUS
 CN Butanedioic acid, 2-[2-[[2-amino-5-(4-chlorophenyl)-6-ethyl-4-pyrimidinyl]amino]-2-oxoethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



L16 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1990:591849 CAPLUS

DN 113:191849

TI Isosteric oligonucleotide analogs containing sulfur

IN Benner, Steven Albert

PA Switz.

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912060	A1	19891214	WO 1989-US2323	19890526
	W: AU, JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 5216141	A	19930601	US 1988-202528	19880606
	AU 8937654	A1	19900105	AU 1989-37654	19890526
	AU 635209	B2	19930318		
	EP 418309	A1	19910327	EP 1989-906936	19890526
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03505452	T2	19911128	JP 1989-506581	19890526
PRAI	US 1988-202528	A	19880606		
	WO 1989-US2323	A	19890526		
AB	Oligonucleotides contg. isosteric S linkages instead of a phosphate, e.g. I, which are resistant to chem. and in vivo enzymic degrdn., lipophilic, and thereby easily cross biol. barriers, and thus useful as, e.g. probes for cDNA, can be prepd. from rigid or flexible isosteric building blocks [II, III, and IV; X = O, CH2; R = OH, R1 = SH; or R = SH, R1 = OH; B = heterocycle ring selected from (aza)pyrimidine, (aza)purine, pyrrolopyrimidine, pyrazolopyrimidine, triazolopyrimidine, imidazolopyrimidine, pyrrolopyridine, pyrazolopyridine, and triazolopyridine, which may be functionalized with NH2, HO, halo, acylamino, or acylhydroxy]. Thus, ozonolysis of 2-(pivaloyloxymethyl)cyclohex-4-enol (V; R3 = pivaloyl) (prepn. given) in MeOH and treatment of the resulting 3,4-trans-1-methoxy-3-pivaloyloxymethyl-4-(2'-hydroxyethyl)tetrahydrofuran with Dowex W50 in refluxing PhMe gave a 2,8-dioxa[1.2.3]bicyclooctane (VI) which was stirred 15 h at room temp. with bis(trimethylsilyloxy)pyrimidine in the presence of CF3SO3SiMe3 in MeCN to give II (X = O, R = OH, R1 = pivaloyloxy, B = 1-uracilyl). Reaction of the latter with EtO2CN:NCO2Et, Ph3P, and AcSH in THF gave II (X = O, R = SAC, R1 = pivaloyloxy, B = 1-uracilyl) which could be conveniently stored and deprotected immediately prior to condensation, by redn. with LiBEt3H (super-hydride) in THF to give a bishomonucleoside II (X = O, R = SH, R1 = OH, B = 1-uracilyl). No synthetic examples for I or other oligonucleotides but only synthetic schemes were given. I bind to complementary A-C-C-T-C-C-T (no data).				
IT	128435-43-8P 128435-44-9P 128453-43-0P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(prepn. of, as intermediate for acyclic nucleoside analog)				
RN	128435-43-8 CAPLUS				
CN	Butanoic acid, 4,4'-dithiobis[2-[(2-amino-6-chloro-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 128435-44-9 CAPLUS

CN Butanoic acid, 4,4'-dithiobis[2-[(2,5-diamino-6-chloro-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 128453-43-0 CAPLUS

CN Butanoic acid, 4,4'-dithiobis[2-[(2-amino-6-chloro-5-[(4-chlorophenyl)azo]-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



L16 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1990:139840 CAPLUS

DN 112:139840

TI Preparation of new peptides as antiviral agents

IN Marumoto, Ryuji; Fukuda, Tsunehiko

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.


CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01226899	A2	19890911	JP 1988-54651	19880308
PRAI	JP 1988-54651		19880308		
OS	MARPAT 112:139840				
AB	H(NHCHR2CO)1(NHCHR1CONHCHR2CO)m(NHCHR1CO)nOH [R1 = L- or D-.omega.-nucleo-.alpha.-amino acid residue; R2 = L- or D-.alpha.-amino acid residue except .omega.-nucleo-.alpha.-amino acid residue; 1, n = 0, 1; m .gtoreq.1 integer], useful as antivirals, esp. useful as inhibitors for HBV virus, and for diagnosis of sickleemia, Down's syndrome, and hepatitis (no data), are prep'd. H-L-Ser-(L-willardine)-L-Ser-(L-willardine)-L-Ser-(L-9-adenylalanine)-L-Ser-L-willardine)-L-Ser-(L-9-adenylalanine)-Gly-OH was prep'd. using a automated peptide synthesizer by condensing amino acid units such as adenylaminopropionic acid deriv. I (prepn. given).				
IT	125883-42-3P 125883-43-4P 125883-45-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and reaction of, in prepn. of antiviral peptide)				
RN	125883-42-3 CAPLUS				
CN	Butanoic acid, 2-amino-4-[(2-amino-6-chloro-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)				



RN 125883-43-4 CAPLUS


CN Butanoic acid, 2-amino-4-[(2-amino-6-chloro-5-[(4-chlorophenyl)azo]-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



09/907,273 (subgenus around elected species)


RN 125883-45-6 CAPLUS

CN Butanoic acid, 2-amino-4-[(2,5-diamino-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1987:214262 CAPLUS
 DN 106:214262
 TI Bridged isocytosine-adenosine compounds: synthesis and antibacterial evaluation
 AU Lever, O. William, Jr.; Vestal, B. Randall
 CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
 SO Journal of Heterocyclic Chemistry (1986), 23(3), 901-3
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 106:214262
 AB Twelve title compds. I (R = NO, NO₂; n = 2, 3, 4, 5, 6, 7) were prep'd. from the corresponding H₂N(CH₂)_nCO₂H by sequential N-benzylloxycarbonylation with PhCH₂OCOCl, conversion to active esters by treatment with N-hydroxysuccinimide, amidation with 5'-amino-5'-deoxyadenosine, hydrogenolysis to remove the benzylloxycarbonyl group, and coupling with 6-(methylthio)-5-nitrosoisocytosine or 6-chloro-5-nitroisocytosine. I showed no significant antibacterial activity when tested in vitro against 22 bacterial strains at 30 .mu.g/mL.
 IT 108257-25-6P 108257-26-7P 108257-27-8P
 108257-28-9P 108257-30-3P 108257-31-4P
 108257-32-5P 108257-33-6P 108282-48-0P
 108318-63-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 108257-25-6 CAPLUS
 CN Adenosine, 5'-[[3-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopropyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-26-7 CAPLUS
 CN Adenosine, 5'-[[4-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxobutyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-27-8 CAPLUS

CN Adenosine, 5'-(6-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxohexyl)amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-28-9 CAPLUS

CN Adenosine, 5'-(7-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxoheptyl)amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-30-3 CAPLUS

CN Adenosine, 5'-(3-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopropyl)amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-31-4 CAPLUS

CN Adenosine, 5'-(4-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxobutyl]amino)-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-32-5 CAPLUS

CN Adenosine, 5'-(5-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxopentyl)amino)-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-33-6 CAPLUS

CN Adenosine, 5'-[[7-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxoheptyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108282-48-0 CAPLUS

CN Adenosine, 5'-[[5-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopentyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 108318-63-4 CAPLUS

CN Adenosine, 5'-[[6-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxohexyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L16 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:207022 CAPLUS
 DN 104:207022
 TI Specific inhibitors in vitamin biosyntheses. Part 8. Syntheses of some functionalized 7,7-dialkyl-7,8-dihydropterins
 AU Cameron, Robert; Nicholson, Sydney H.; Robinson, David H.; Suckling, Colin J.; Wood, Hamish C. S.
 CS Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, G1 1XL, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1985), (10), 2133-43
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 104:207022
 AB The functionalized blocked 7,8-dihydropteridines I (R = OH, R1 = 4-ClC6H4CH2; R = H, R1 = OH, CH2CO2H; R = 2,4,5-C13C6H2O, R1 = H) and II were prep'd. The functional groups were chosen to provide compds. with potential for investigating the protein chem. of enzymes in the pathway leading to dihydrofolate and, in particular, of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase. The potential of 7-substituents to provide sites of attachment of inhibitors to columns for affinity chromatog. was explored but the extent of the study was curtailed by the restricted applicability of NOCl addn. to alkenes, a reaction used in the synthesis of precursors for I and II. I (R = 2,4,5-C13C6H2O, R1 = H) and II were designed to have enhanced transport properties.
 IT 102222-95-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyclization of)
 RN 102222-95-7 CAPLUS
 CN Hexanoic acid, 4-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-4-methyl-5-oxo- (9CI) (CA INDEX NAME)




L16 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1983:605528 CAPLUS
 DN 99:205528
 TI Minoxidil sulfate, a metabolite of minoxidil
 AU Johnson, Garland A.; Barsuhn, Karen J.; McCall, John M.
 CS Cardiovasc. Dis. Res. Cent. Nerv. Syst. Dis. Res., Upjohn Co., Kalamazoo, MI, USA
 SO Drug Metabolism and Disposition (1983), 11(5), 507-8
 CODEN: DMDSAI; ISSN: 0090-9556
 DT Journal
 LA English
 AB Following the i.v. administration of labeled minoxidil (I) [38304-91-5] to rats, reversed-phase high-pressure liq. chromatog. of bile of I-treated rats confirmed the presence of known I-metabolites as well as a previously unknown metabolite, minoxidil sulfate [83701-22-8]. Minoxidil sulfate comprised a small portion of the total radioactivity in the bile, i.e. 3% of the total, and it produced a distinct peak in the profile of biliary I metabolites.
 IT 56828-38-7
 RL: BIOL (Biological study)
 (as minoxidil metabolite)
 RN 56828-38-7 CAPLUS
 CN Pentanoic acid, 5-[(2,6-diamino-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1983:437986 CAPLUS
 DN 99:37986
 TI Detection of C-nitroso dimer formation by field desorption mass spectrometry
 AU Johnson, R. L.; Lever, O. W., Jr.; Brent, D. A.
 CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
 SO Organic Mass Spectrometry (1983), 18(1), 36-41
 CODEN: ORMSBG; ISSN: 0030-493X
 DT Journal
 LA English
 AB Field desorption mass spectrometry showed $\text{Me}_2\text{CClCH}(\text{NO})\text{CH}_2\text{OR}$ (R = cyclohexyl, PhCH₂, Me, cyclopentyl) (I-IV, resp.) to exist as dimers whereas p-O₂NC₆H₄NHPh and pyrimidines V [R = Me, (CH₂)₅CO₂H] are monomeric. Mixed dimers of II with I, III, and IV and I with IV were also obsd. using the technique.
 IT 86296-76-6
 RL: PRP (Properties)
 (mass spectrum of, field desorption)
 RN 86296-76-6 CAPLUS
 CN Hexanoic acid, 6-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1979:137759 CAPLUS
 DN 90:137759
 TI The reaction of 2,4-diamino-6-piperidinopyrimidine 3-oxide with acid anhydrides
 AU McCall, John M.; TenBrink, Ruth E.; Royer, Max E.; Ko, Howard
 CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA
 SO Journal of Heterocyclic Chemistry (1978), 15(8), 1529-30
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB Reaction of the title compd. I (R = R1 = H) with 1 equiv. of Ac2O gave 26:1 I (R = Ac, R1 = H) and I (R = H, R1 = Ac). Bz2O reacted similarly to give a 16:1 ratio of the corresponding amides. Excess anhydrides gave the diamides. Reaction of I (R = R1 = H) with glutaric anhydride gave only I (R = CO(CH2)3CO2H, R1 = H).
 IT 69729-67-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 69729-67-5 CAPLUS
 CN Pentanoic acid, 5-[[2-amino-3-oxido-6-(1-piperidinyl)-4-pyrimidinyl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1977:593445 CAPLUS
 DN 87:193445
 TI Radioimmunoassay of minoxidil in human serum
 AU Royer, Max E.; Ko, Howard; Gilbertson, Terry J.; McCall, John M.;
 Johnston, Karen T.; Stryd, Ronald
 CS Drug Metab. Res. Sect., Upjohn Co., Kalamazoo, MI, USA
 SO Journal of Pharmaceutical Sciences (1977), 66(9), 1266-9
 CODEN: JPMSEA; ISSN: 0022-3549
 DT Journal
 LA English
 AB A simple, sensitive, and specific radioimmunoassay for detg. minoxidil (I) [38304-91-5] was developed. Rabbit antiserum to 2 I haptens were compared for cross-reactivity and assay levels on human serums. One antiserum had little cross-reactivity with I metabolites. The radioimmunoassay is specific for detg. I directly in serum without extn. Human serum I levels were detd. from a single oral dose. The limit of detection was 3.02 ng/mL.
 IT 64675-16-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and immune cross-reactions of, with minoxidil)
 RN 64675-16-7 CAPLUS
 CN Pentanoic acid, 5-[[2-amino-3-oxido-6-(1-piperidinyl)-4-pyrimidinyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1977:453368 CAPLUS
 DN 87:53368
 TI 2,4-Diaminopyrimidine derivatives
 PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain
 SO Span., 9 pp.
 CODEN: SPXXAD

DT Patent
 LA Spanish

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 431918	A1	19761101	ES 1974-431918	19741114
PRAI	ES 1974-431918		19741114		
AB	Amides I (R = H, X = o-C ₆ H ₄ ; R = 3,4,5-(MeO)3C ₆ H ₂ CH ₂ , X = CH:CH, CH ₂ CH ₂) were prep'd. by acylating 2,4-pyrimidinediamines with the appropriate anhydrides.				

IT 63271-78-3P 63306-49-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 63271-78-3 CAPLUS


CN Butanoic acid, 4-[[2-amino-5-[(3,4,5-trimethoxyphenyl)methyl]-4-pyrimidinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 63306-49-0 CAPLUS

CN 2-Butenoic acid, 4-[[2-amino-5-[(3,4,5-trimethoxyphenyl)methyl]-4-pyrimidinyl]amino]-4-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1977:189996 CAPLUS

DN 86:189996

TI 2-Amino-4-(carboxyacetylamo)pyrimidine bismuth salts

PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain

SO Span., 8 pp.

CODEN: SPXXAD

DT Patent

LA Spanish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 432523	A1	19760901	ES 1974-432523	19741203
PRAI	ES 1974-432523		19741203		

AB The pyrimidine compds. I (R = H, PhCH₂ or methoxybenzyl; Z = alkylene, arylene) were converted into the Bi salts by treatment with yellow Bi oxide, freshly prépd. from Bi(NO₃)₃ and aq. NaOH, in a solvent or mixt. of solvents of 10 .mu. polarity. Thus, a mixt. of I [R = H, Z = (CH₂)₃] and Bi oxide in 210 L n-hexane and 1.5 L H₂O was stored at 65.degree.C for <10 h to give the Bi salt. Also prépd. was the Bi salt of I [R = 3,4,5-(MeO)₃C₆H₂, Z = (CH₂)₂].


IT 62668-05-7

RL: PROC (Process)

(conversion of, to bismuth salt)

RN 62668-05-7 CAPLUS

CN Pentanoic acid, 5-[(2-amino-4-pyrimidinyl)amino]-5-oxo- (9CI) (CA INDEX NAME)




IT 62668-06-8P 62668-08-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 62668-06-8 CAPLUS


CN Pentanoic acid, 5-[(2-amino-4-pyrimidinyl)amino]-5-oxo-, bismuth salt (9CI) (CA INDEX NAME)



●x Bi(x)

RN 62668-08-0 CAPLUS

CN Butanoic acid, 4-[(2-amino-5-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl)amino]-4-oxo-, bismuth salt (9CI) (CA INDEX NAME)




• $x \in Bi(x)$

IT 62668-07-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with pyrimidinediamine carboxyacetyl derivs.)

RN 62668-07-9 CAPLUS

CN Butanoic acid, 4-[[2-amino-5-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1977:189848 CAPLUS

DN 86:189848

TI Synthesis of compounds related to antitumor agents. V. On the reaction of aliphatic carboxylates with 2,4-diamino-5-hydroxy-6-methylpyrimidine

AU Kato, Tetsuo; Oda, Noriichi; Ito, Isao

CS Fac. Pharm. Sci., Nagoya City Univ., Nagoya, Japan

SO Chemical & Pharmaceutical Bulletin (1977), 25(3), 491-4

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English


AB 2,4-Diamino-5-hydroxy-6-methylpyrimidine (I) was treated with $\text{CH}_2(\text{CO}_2\text{Et})_2$ at 140-50.degree. to give pyrimidine II ($\text{R} = \text{OH}$, $\text{R}_1 = \text{OEt}$, $\text{R}_2 = \text{CH}_2\text{CO}_2\text{Et}$) which was treated with HOAc at 40-50.degree. for 10 min to give a mixt. of pyrimido[5,4-d][1,4]oxazepine III ($\text{R}_3 = \text{OH}$, $\text{R}_4 = \text{OEt}$, $\text{R}_5 = \text{Ac}$) (IV) and dihydrooxazolo[4,5-d]pyrimidine V. IV was refluxed in EtOH for 8 h to give III ($\text{R}_3\text{R}_4 = \text{O}$, $\text{R}_5 = \text{Ac}$) which was deacetylated and lactone-cleaved by hydrolysis with 10% HCl . The resulting hydroxy acid deriv. was recyclized in Me_2SO at 140-150.degree. for 20 min. to give III ($\text{R}_3\text{R}_4 = \text{O}$, $\text{R}_5 = \text{H}$). Pyrimido[5,4-b]oxazine VI, oxazolo[4,5-d]pyrimidine VII, and II [$\text{R}\text{R}_1 = \text{O}$, $\text{R}_2 = \text{CH}_2\text{CH}_2\text{CO}_2\text{R}_6$ ($\text{R}_6 = \text{Me}$, Et)] were also prepd. from I.

IT 62812-12-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and lactonization of)

RN 62812-12-8 CAPLUS


CN Propanoic acid, 3-[(2-amino-5-hydroxy-6-methyl-4-pyrimidinyl)amino]-3-oxo- (9CI) (CA INDEX NAME)




L16 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1975:588142 CAPLUS
 DN 83:188142
 TI Metabolism of minoxidil, a new hypotensive agent. II. Biotransformation following oral administration to rats, dogs, and monkeys
 AU Thomas, Richard C.; Harpootlian, Harry
 CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA
 SO Journal of Pharmaceutical Sciences (1975), 64(8), 1366-71
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English
 AB The biotransformation of minoxidil (I) [38304-91-5] was studied in the rat, dog, and monkey and compared to reported results in the human. Each species excreted substantially the same metabolites, but in quite different relative amounts. The monkey and the human exhibited similar metabolite profiles, whereas the dog and rat were quite different from each other and from the monkey and human. The major excretory product for the monkey and human was I glucuronide [56828-40-1]. Substantially smaller amounts of unchanged I, 2,4-diamino-6-(4'-hydroxypiperidino)pyrimidine 3-oxide [56828-37-6], and more polar metabolites also were excreted by these 2 species. The major excretory product in the rat was unchanged I. Almost as much (combined) of the 2 acidic metabolites, 2,4-diamino-6-(4'-carboxy-n-butylamino)pyrimidine [56828-38-7] and its 3-oxide [56828-41-2], also were produced. Smaller amounts of the glucuronide of I, 2,4-diamino-6-(4'-hydroxypiperidino)pyrimidine 3-oxide, its 3'-hydroxy isomer [56828-39-8], and 2,4-diamino-6-piperidinopyrimidine [24867-26-3] also were excreted by the rat. The major metabolite of I excreted by the dog was the 4'-hydroxy metabolite. Smaller amounts of unchanged I and polar metabolites and much smaller amounts of the glucuronide of I, the 3'-hydroxy metabolite, and 2,4-diamino-6-piperidinopyrimidine also were excreted by the dog. Evidence was obtained for a 4'-hydroxy metabolite glucuronide in this species. The major circulatory material in dog plasma was the 4'-hydroxy metabolite, whereas it was the glucuronide of I in monkey plasma.
 IT 56828-38-7 56828-41-2
 RL: BIOL (Biological study)
 (as minoxidil metabolite, species in relation to)
 RN 56828-38-7 CAPLUS
 CN Pentanoic acid, 5-[(2,6-diamino-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 56828-41-2 CAPLUS
 CN Pentanoic acid, 5-[(2,6-diamino-1-oxido-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1975:38479 CAPLUS
 DN 82:38479
 TI Synthesis and antifolate activity of isoaminopterin
 AU Nair, M. G.; Mercer, L. P.; Baugh, Charles M.
 CS Dep. Biochem., Univ. South Alabama, Mobile, AL, USA
 SO Journal of Medicinal Chemistry (1974), 17(12), 1268-72
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 AB Isoaminopterin (I) [53661-94-2], a candidate antitumor agent, inhibited growth of folate-requiring *Lactobacillus casei* and *Streptococcus faecium* at ED50 0.90 .times. 10-13 and 45 .times. 10-13M, resp., and inhibited dihydrofolate reductase [9002-03-3] from *L. casei* by 50% at 14.5 .times. 10-9M. These were similar to the effective concns. of methotrexate [59-05-2]. It was prep'd. by a modification of the isofolic acid synthesis by W. R. Boon and T. Leigh (1951), or by an alternate procedure involving coupling of 6-chloro-2,4-diaminopteridine [17714-06-6] with .alpha.-amino-p-toluic acid [56-91-7].
 IT 53661-96-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclization of)
 RN 53661-96-4 CAPLUS
 CN Benzoic acid, 4-[[[[2,5,6-triamino-4-pyrimidinyl)amino]acetyl]amino]methyl]-(9CI) (CA INDEX NAME)




IT 53661-95-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. and redn. of)
 RN 53661-95-3 CAPLUS
 CN Benzoic acid, 4-[[[[2,6-diamino-5-nitro-4-pyrimidinyl)amino]acetyl]amino]methyl]-(9CI) (CA INDEX NAME)




L16 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:146111 CAPLUS
 DN 80:146111
 TI Pteridines. LX. Synthesis and autoxidation of 7,8-dihydroxanthopterins
 AU Pfleiderer, Wolfgang
 CS Fachbereich Chem., Univ. Konstanz, Constance, Fed. Rep. Ger.
 SO Chemische Berichte (1974), 107(3), 785-95
 CODEN: CHBEAM; ISSN: 0009-2940
 DT Journal
 LA German
 AB Reaction of the chloropyrimidines I with R₃NHCR₄R₅CO₂Et and ring closure of the resulting aminopyrimidines II gave the title xanthopterins III (R₁-R₅ = H or Me, R₆ = H). Similarly prep'd. was III (R₁-R₅ = H, R₆ = Me). The pKa values and uv spectra were detd. The monoanions of III were subject to autoxidn., which was catalyzed by NH₃ and primary angles.
 IT 1154-85-4P 14508-66-8P 14699-57-1P
 52296-01-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 1154-85-4 CAPLUS
 CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14508-66-8 CAPLUS
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 14699-57-1 CAPLUS
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 52296-01-2 CAPLUS

CN L-Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:128131 CAPLUS
 DN 80:128131
 TI Synthesis and biological evaluation of isofolic acid
 AU Nair, M. G.; Baugh, Charles M.
 CS Nutr. Program, Univ. Alabama, Birmingham, AL, USA
 SO Journal of Medicinal Chemistry (1974), 117(2), 223-6
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 AB Isofolic acid (I) [52560-13-1] was prep'd. by displacement reaction of N-glycyl-.alpha.-amino-p-toluic acid [51542-05-3] with 2-amino-6-chloro-5-nitro-4(3H)-pyrimidinone [1007-99-4], dithionite redn. of the nitro group, thermal cyclization, and MnO₂ oxidn. to isopteroic acid (II) [51542-06-4], which was coupled with di-Et glutamate by the mixed anhydride method. I and II were comparable to methotrexate [59-05-2] as inhibitors of *Streptococcus faecium*, while *Lactobacillus casei* was inhibited by I but not by II. The implications of the use of II as a specific inhibitor of organisms capable of attaching the terminal glutamyl moiety to the mol. were discussed.
 IT 52121-32-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 52121-32-1 CAPLUS
 CN Benzoic acid, 4-[[[[2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]acetyl]amino]methyl] - (9CI) (CA INDEX NAME)




IT 52121-33-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (thermal cyclization of)
 RN 52121-33-2 CAPLUS
 CN Benzoic acid, 4-[[[[2,5-diamino-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]acetyl]amino]methyl] - (9CI) (CA INDEX NAME)




L16 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:37077 CAPLUS
 DN 80:37077
 TI Synthesis and electrophilic bromination of 2-methyl-9-carbethoxy-1,3,4,7-tetraazacycl[3.3.3]azine
 AU Ceder, Olof; Rosen, Kenneth
 CS Chalmers Inst. Technol., Univ. Goteborg, Goteborg, Swed.
 SO Acta Chemica Scandinavica (1947-1973) (1973), 27(7), 2421-5
 CODEN: ACSAA4; ISSN: 0001-5393
 DT Journal
 LA English
 AB 1,3,4,7-Tetraazacycl[3.3.3]azine (I, R = H) was prep'd. from 2,4-diaminopyrimidine and EtOCH:C(CN)CO₂Et. Electrophilic bromination of I (R = H) gave I (R = Br).
 IT 51138-31-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 51138-31-9 CAPLUS
 CN 2-Propenoic acid, 3-[(2-amino-4-pyrimidinyl)amino]-2-cyano-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




L16 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:85762 CAPLUS
 DN 66:85762
 TI Synthesis of some N-methylated pteridines related to 7,8-dihydroxanthopterin
 AU Zondler, Helmut; Forrest, Hugh S.; Lagowski, Jeanne M.
 CS Univ. of Texas, Austin, TX, USA
 SO Journal of Heterocyclic Chemistry (1967), 4(1), 12-15
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB Seven methylated pteridines were synthesized by condensation of a 4-chloro-5-nitropyrimidine with a .beta.-oxoamine (or a blocked deriv.), redn. of the nitro group, and subsequent ring closure. This scheme provides a new route to dihydroxanthopterin (I). Several cases are reported, however, in the uracil series where ring closure could not be effected.
 IT 14508-66-8P 14699-57-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 14508-66-8 CAPLUS
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 14699-57-1 CAPLUS
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1965:29707 CAPLUS
 DN 62:29707
 OREF 62:5278h,5279a-b
 TI Pteridine derivatives. IX. 2,6-Diamino-4-hydroxypteridine and related dihydropteridines
 AU Stuart, Alexander; West, D. W.; Wood, H. C. S.
 CS Roy. Coll. Sci. Technol., Glasgow, UK
 SO J. Chem. Soc. (1964), (Dec.), 4769-74
 DT Journal
 LA English
 AB cf CA 55, 11422i. An unambiguous synthesis of 2,6-diamino-4-hydroxypteridine is described and the product is shown to be identical with a specimen isolated by van Baalen and Forrest (CA 53, 15089a) from blue-green algae. The structure of some related dihydropteridines is examd., and in particular the structure of 7,8-dihydroxanthopterin (I) is confirmed.
 IT 1140-88-1, Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- 1154-85-4, Alanine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-2-methyl-, ethyl ester 14699-57-1, Glycine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, ethyl ester (prepn. of)
 RN 1140-88-1 CAPLUS
 CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)




RN 1154-85-4 CAPLUS
 CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 14699-57-1 CAPLUS
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

09/907,273 (subgenus around elected species)




L16 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1965:29706 CAPLUS
 DN 62:29706
 OREF 62:5278f-h
 TI Chemical and kinetic studies on the reaction of 2-hydrazino-3-phenylquinoxaline with carbonyl compounds. I
 AU Tagami, Shoichiro; Shiho, Denitsu
 CS Univ. Toyama, Japan
 SO Yakugaku Zasshi (1964), 84(11), 1085-90
 DT Journal
 LA Japanese
 AB A mixt. of 6.0 g. 2-chloro-3-phenylquinoxaline, 17 g. MeNH₂.HCl, 13 g. Na₂CO₃, and 50 ml. EtOH is heated 7 hrs. in an autoclave at 100-50.degree. to give 5.8 g. 2-methylamino-3-phenylquinoxaline (I), pale yellow needles, m. 132.degree. (dil. MeOH). I (4.8 g.) in 400 ml. H₂O is treated overnight with 80 ml. concd. HCl and 2.4 g. NaNO₂ and the resulting nitrosoamine compd. (pale yellow needles, m. 109.5.degree. (Me₂CO)) (1.31 g.) is reduced in 70 ml. Et₂O by using 20 ml. ethereal soln. of 0.19 g. LiAlH₄ to give 2-(1-methylhydrazino)-3-phenylquinoxaline (II); HCl salt m. 245.degree. (decompn.). II (0.25 g.) is dissolved in a small amt. of EtOH and kept at room temp. with 0.0015 mole aldehyde to give the following III (R and m.p. given): Ph, 181.5.degree.; p-ClC₆H₄, 115.degree.; p-NO₂C₆H₄, 171.degree.. Pyrolysis of III gives the corresponding 1-substituted s-triazolo [4,3-a] quinoxaline with concurrent elimination of a hydrocarbon. Factors which apparently govern the elimination of alkyl groups from III are discussed. Also, the kinetic of the pyrolysis reaction are studied and the mechanisms for this type of cleavage presented.
 IT 1140-88-1, Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- 1154-85-4, Alanine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-2-methyl-, ethyl ester 14699-57-1, Glycine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, ethyl ester (prepn. of)
 RN 1140-88-1 CAPLUS
 CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)

Jan 20
 6/20




RN 1154-85-4. CAPLUS
 CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS

CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester
(9CI) (CA INDEX NAME)



L16 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1964:486219 CAPLUS

DN 61:86219

OREF 61:15066h,15067a-c

TI Effect of a number of N-pyrimidyl amino acids and of some of their 5-arylazo derivatives on the growth of certain microorganisms

AU Roy-Burman, P.; Sen, D.

CS Univ. Coll. Sci. Technol., Calcutta

SO Biochem. Pharmacol. (1964), 13(10), 1437-49

DT Journal


LA Unavailable

AB Sixteen new N-pyrimidyl amino acids were obtained by substitution at the C-2, C-4, or C-6 position of 2,4-diamino-6-methylpyrimidine by aromatic amino acids or different carboxyalkyl amino groups (i.e., aliphatic amino acid moiety). These compds. were tested for their effect on the growth of *Streptococcus faecalis*, *Lactobacillus arabinosus*, and *Escherichia coli*. The new compds., 2,4-diamino-5-arylazo-6-methylpyrimidine and six N-(5-arylazo-4-pyrimidyl) amino acids, were also studied.2,4-Diamino-6-methylpyrimidine inhibited growth of all 3 microorganisms tested, but substitution at the C-2, C-4, or C-6 position by carboxyalkyl amino groups produced compds. with little or no inhibitory effects. The three N-pyrimidyl compds. substituted with aromatic amino acids inhibited growth but were less effective than the parent compd. All the 5-arylazopyrimidines significantly inhibited growth of *S. faecalis* and, to a lesser extent, *L. arabinosus*. It was observed that among these compds. the inhibitory activity decreased with increase in the bulk of the amino acid moiety. Investigation of the mechanism of the inhibitory action of these compds. in *S. faecalis* revealed that they acted primarily as folic acid antagonists in a manner consistent with an assumption that they interfere with the enzymic conversion of folic acid to N5-formyltetrahydrofolic acid in *S. faecalis*.

IT 93727-00-5, Benzoic acid, p-[(2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl)azo]- 94093-95-5, Benzoic acid, p-[(2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl)azo]- 94264-54-7, Benzoic acid, p-[(2-amino-4-[(1-carboxy-2-methylbutyl)amino]-6-methyl-5-pyrimidinyl)azo]- 96063-58-0, Benzoic acid, p-[(2-amino-4-[(.alpha.-carboxyphenethyl)amino]-6-methyl-5-pyrimidinyl)azo]- (bactericidal activity of)


RN 93727-00-5 CAPLUS

CN Benzoic acid, p-[(2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAPLUS


CN Benzoic acid, p-[(2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)



RN 94264-54-7 CAPLUS
 CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)




RN 96063-58-0 CAPLUS
 CN Hydrocinnamic acid, .alpha.-[(2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




IT 89465-54-3, Glycine, N-(2,6-diamino-4-pyrimidinyl)-
 89897-36-9, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-
 90198-25-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-
 90198-46-2, Serine, N-(2-amino-6-methyl-4-pyrimidinyl)-
 90649-20-0, Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- 91253-20-2, Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)-
 91253-21-3, Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- 91717-29-2, Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- 92296-32-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-
 (prepn. and bactericidal activity of)


RN 89465-54-3 CAPLUS
 CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 89897-36-9 CAPLUS
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-46-2 CAPLUS
CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90649-20-0 CAPLUS
CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




RN 91253-20-2 CAPLUS
CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91253-21-3 CAPLUS
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91717-29-2 CAPLUS
CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)




L16 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1964:60902 CAPLUS
 DN 60:60902
 OREF 60:10680g-h,10681a-b
 TI Pyrimidines. IV. Derivatives of 2-amino-4-methyl-6-hydroxypyrimidine
 AU Fel'dman, I. Kh.
 SO Tr. Leningr. Khim.-Farmatsevt. Inst. (1962), (16), 25-8
 DT Journal
 LA Unavailable
 AB cf. CA 55, 21136c, 23544f. For chem. and biol. study, a series of derivs. of I (R = OH) (Ia) was obtained. Ia (14.5 g.) and 30 ml. POCl₃ were heated at 100.degree. 3 hrs., excess POCl₃ removed under vacuum, ice, added, and NH₄OH added to ppt. I (R = Cl) (Ib), 89%, m. 180-2.degree. (C₂H₄Cl₂); Ac deriv. formed. I (R = SH) (Ic) treated with Ac₂O gave the Ac deriv. of Ic, C₇H₉N₃OS, m. 133-4.degree. (50% alc.). Ia (5 g.), 10 ml. ethylene oxide, and 15 ml. water were heated in a sealed tube at 50.degree. 10 hrs. to give 1-(.beta.-hydroxyethyl)-2-amino-4-methyldihydro-6-pyrimidinone, yield 68%, m. 187-8.degree. (1:2 alc.-ether), 1.69 g. of which and 1 ml. SOCl₂ were heated to soln. and cooled to give 1-(.beta.-chloroethyl)-2-amino-4-methyldihydro-6-pyrimidinone-HCl, yield 62%, m. 215-16.degree. (alc.). To a soln. of Ia (0.625 g.) in 3 ml. 15% NaOH with cooling, 0.8 g. MeSO₂Cl is added to give I (R = MeSO₃), 70%, m. 138-9.degree. (alc.). A mixt. of 1.4 g. Ib and 10 ml. BuOH was heated to soln., 1.05 g. HN-(CH₂CH₂OH)₂ added, and the mixt. stirred at 130-40.degree. 6 hrs. to give I.HCl [R = N(CH₂CH₂OH)₂] (Id), 80%, m. 165-6.degree. (Me-OH). Id (2.5 g.) and 15 ml. dichloroethane was treated with cooling with 3 ml. SOCl₂ dropwise, and the mixt. heated at 80.degree. 20 min. and kept several hrs. to give I.HCl [R = N(CH₂CH₂Cl)₂], yield 93%, m. 214-15.degree. (MeOH). Ib (5.72 g.), 9 g. H₂NCH₂CO₂H, 2 g. Et₃N, and 25 ml. HCONMe₂ was stirred 80-5 hrs. at 90-100.degree. to give I.HCl (R = NHCH₂CO₂H), m. 171-3.degree. (alc.). Ib (2.86 g.), 2 ml. H₂NCH₂CO₂Et, and 13 ml. HCONMe₂ was heated at 70-80.degree. 68-70 hrs. to give I.HCl (R = NHCH₂CO₂Et), m. 218-19.degree. (alc.).
 IT 92385-16-5, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride 93263-85-5, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (prepn. of)
 RN 92385-16-5 CAPLUS
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (7CI) (CA INDEX NAME)



● x HCl


RN 93263-85-5 CAPLUS
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)

09/907,273 (subgenus around elected species)




● x HCl


L16 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1964:9987 CAPLUS
 DN 60:9987
 OREF 60:1829e-g
 TI Potential antimetabolites. VII. Substituted N-4-pyrimidyl amino acids and their derivatives
 AU Shvachkin, Yu. P.; Berestenko, M. K.
 CS State Univ., Moscow
 SO Zh. Obshch. Khim. (1963), 33(9), 2842-8
 DT Journal
 LA Unavailable
 AB cf. CA 58, 3425a; 60, 654e. The following were prep'd. as potential antimetabolites in protein-nucleic metabolism. PhCH₂CH(NH₂)CO₂H refluxed in aq. NaOH with 2-amino-4chloro-5-nitro-6-methylpyrimidine (I) 40 min. gave after treatment with AcOH 72.8% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)phenylalanine, decompd. 219-20.degree., .LAMBDA. 260 and 368-72 m.mu.; also formed in 41.7% yield from the corresponding Me ester (II) refluxed 3 hrs. in 2N HCl. Di-Na glutamate similarly gave 82.7% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)glutamic acid, decompd. 213-14.degree., .LAMBDA. 367-9 m.mu.. Similarly, arginine gave 53.6% .alpha.-N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)arginine, m. 203-5.degree., .LAMBDA. 362-4 and 364-5 m.mu.. Phenylalanine Me ester-HCl treated with MeONa-MeOH at 0.degree., then with I, finally at room temp. 40 min., gave 54.2% II, m. 173.degree., .LAMBDA. 260-1 and 358 m.mu., which also formed by esterifying the free amino acid with MeOHHCl 3 hrs. at reflux and 12 hrs. at room temp. in 92.1% yield. Similarly tyrosine Me ester-HCl and I in MeONa-MeOH-Me₂CO gave in 0.5 hr. at 0.degree. and 1 hr. at room temp. 54.6% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)tyrosine Me ester, m. 173.degree., .LAMBDA. 259 and 361-3 m.mu.. Similarly were prep'd.: N-(2-amino-5-nitro-6methyl-14-pyrimidyl) valine Me ester, 70.4%, m. 163.degree., 259 and 362-5 m.mu.; N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)leucine Me ester, 65, m. 153.degree., .LAMBDA. 261 and 360 m.mu.; N-(2-amino-5-nitro-6methyl-4-pyrimidyl)glutamic acid di-Me ester, 46.7, m. 112.degree., .LAMBDA. 257-9 and 360 m.mu.; N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)phenylalanylglutamic acid Me ester, 58, m. 170-1.degree. (MeOH), .LAMBDA. 262 and 362-3 m.mu.. The electrophoretic mobilities in 30% AcOH or in 0.1N borax are reported, as are the R_f values on paper in isoProH-NH₄OH-H₂O, BuOH-H₂O-AcOH, and BuOH satd. with H₂O.
 IT 91194-85-3, Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 92286-86-7, Arginine, N₂-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- 93002-46-1, Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 93537-11-2, Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 94823-79-7, Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester
 (prep'n. of)
 RN 91194-85-3 CAPLUS
 CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)
 (CA INDEX NAME)




RN 92286-86-7 CAPLUS
 CN Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 93002-46-1 CAPLUS
 CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAPLUS
 CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAPLUS

CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:462818 CAPLUS

DN 59:62818

OREF 59:11651c-d

TI Structure of proteins. VIII. Preparation of nitropyrimidylamino acids

AU Scoffone, Ernesto; Signor, Angelo; Biondi, Laura

CS Univ. Padua, Italy

SO Gazz. Chim. Ital (1963), 93(1-2), 81-9

DT Journal


LA Unavailable

AB 2-Chloro-5-nitro- (I), 2-methyl-4-chloro-5-nitro-6-amino-(II), and 2-amino-4-chloro-5-nitro-6-methylpyrimidine (III) were similarly treated with amino acids (amino acid and m.p. derivs. with I, II, III given): glycine, 188.degree., 290.degree., 240.degree.; DL-alanine, 187.degree., 253.degree., 230.degree.; DL-serine, 208.degree., 240.degree., 220.degree.; DL-valine, 151.degree., --, 220.degree.; L-leucine, 94.degree., 240.degree., --; DL-phenylalanine, 193.degree., 236.degree., 210.degree.; L-proline (IV), 178.degree., 260.degree., 135.degree.; L-tyrosine --, --, 164.degree.. All I derivs. had λ useful for detn. at 340 \pm 2 m.mu. (except IV, 360 m.mu.), II derivs., at 345 m.mu. (IV, 340 m.mu.), and III derivs., at 361 m.mu. (IV 380 m.mu.) and 260 m.mu. (IV, 274 m.mu.). The stability of these derivs. was greater than of the pyridine derivs.; leucine and phenylalanine derivs. with II gave a 0% hydrolysis test. II is the preferred reagent.


IT 89854-39-7, Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-
(prepn. of)

RN 89854-39-7 CAPLUS

CN Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L16 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1963:73327 CAPLUS
 DN 58:73327
 OREF 58:12559b-c
 TI Synthesis of some N-pyrimidylamino acids. III
 AU Roy-Burman, P.; Sen, D.
 CS Univ. Colls. Sci. Technol., Calcutta
 SO Naturwissenschaften (1962), 49, 494-5
 DT Journal
 LA English
 AB cf. CA 57, 824b. The following were prep'd.: I [R = CH(CH₂OH)CO₂H], m. 213-14.degree. (decompn.), λ 270 m.mu.; I (R = C₆H₄CO₂H-p), chars without melting 338-40.degree., λ 300 m.mu.; I (R = CH₂CONHNH₂), m. 205-9.degree., λ 270 m.mu.; II (R = C₆H₄CO₂H-p), m. 312.degree. (decompn.) λ 272 and 310 m.mu.; II (R = C₆H₄SO₃H-p, m. >360.degree., λ 265 and 305 m.mu.; and III (R = CH₂CO₂H), m. >360.degree., λ 275 m.mu..
 IT 89465-54-3, Glycine, N-(2,6-diamino-4-pyrimidinyl)-
 (prepn. of)
 RN 89465-54-3 CAPLUS
 CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L16 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:48342 CAPLUS

DN 58:48342

OREF 58:8252g-h,8253a

TI N-(5-Arylazo-4-pyrimidyl)amino acids as growth inhibitors of *Streptococcus faecalis*

AU Roy-Burman, P.; Sen, D.

CS Univ. Calcutta

SO Nature (1962), 196, 1316

DT Journal

LA Unavailable


AB cf. Tanaka, et al., CA 54, 21111g. Seven new compds. were prep'd. (CA 55, 10456f) and their inhibitory action tested on certain microorganisms. All the compds. inhibited the growth of *S. faecalis*, and all were competitive antagonists to pteroylglutamic acid (PGA) and leucovorin. Inhibition of *S. faecalis* was as follows: (concn. .gamma./ml. required for 50% inhibition of growth in the presence of PGA (0.001 .gamma./ml.)): I, 0.105; II (R = H), 1.07; II (R = Me) 2.25; II (R = Et), 2.7; II (R = iso-Pr), 7.19; II (R = sec-Bu), 7.8; II (R: benzyl), 22.8.

IT 94264-54-7, Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]-

(Staphylococcus faecalis response)

RN 94264-54-7 CAPLUS


CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



IT 93727-00-5, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- 94093-95-5, Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- 94264-54-7, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylbutyl)amino]-6-methyl-5-pyrimidinyl]azo]- 96063-58-0, Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (Staphylococcus faecalis response to)


RN 93727-00-5 CAPLUS

CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAPLUS

CN Benzoic acid, p-[(2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)




RN 94264-54-7 CAPLUS

CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)




RN 96063-58-0 CAPLUS


CN Hydrocinnamic acid, α -[(2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)



L16 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1963:20731 CAPLUS
 DN 58:20731
 OREF 58:3425a-c
 TI Nucleophilic displacement reactions in the synthesis of N-4-pyrimidyl amino acids and their derivatives
 AU Shvachkin, Yu. P.; Berestenko, M. K.
 CS State Univ., Moscow
 SO Zh. Obshch. Khim. (1962), 32, 1712-13
 DT Journal
 LA Unavailable
 AB Reaction of 2-amino-4-chloro-5-nitro-6-methylpyrimidine with Na salts or esters of amino acids readily gave I (R given): HO₂CCH(CH₂Ph), decompg. at 219-20.degree.; HO₂CCH(CH₂CH₂CO₂H), decompg. at 213-14.degree.; MeO₂CCH(CH₂Ph), m. 173.degree.; MeO₂CCH(CH₂CH₂CO₂Me), m. 112.degree.; MeO₂CCH(CH₂Me₂), m. 163.degree.; MeO₂CCH(CH₂CHMe₂), m. 153.degree.; MeO₂CCH(CH₂C₆H₄OH-p), m. 173.degree.; MeO₂CCH₂NHCOCH(CH₂Ph), m. 170.degree.. The yields were 46-83%. Ultraviolet max. were given.
 IT 91194-85-3, Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 92295-36-8, Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- 92556-22-4, Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester 93002-46-1, Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 93537-11-2, Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 94823-79-7, Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (prepn. of)
 RN 91194-85-3 CAPLUS
 CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 92295-36-8 CAPLUS
 CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)




RN 92556-22-4 CAPLUS

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)




RN 93002-46-1 CAPLUS

CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAPLUS

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAPLUS

CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1962:404013 CAPLUS

DN 57:4013

BN 57:4015

II Synthesis of some N-pyrimidyl amino acids. II

II Synthesis of some N-pyridyl aryls
AU Roy-Burman, P. ; Len, D. ; Guha, B. C.

AS Roy Burman, P., Beh, D., Guna, B. C.
CS Univ. Colls. Sci. and Technol., Calcutta

SO Naturwissenschaften (1961) 48: 737

50 *Landwissenschaften* (1961), 40, 751
DT *Journal*

LA English

III English
AB cf. CA


AL CI. CA 55, 104501. Various substituted carboxyalkylaminopyrimidines (I) were prep'd. to give compds. with possible effect on tumor growth and on the growth of various microorganisms. The following I were obtained [R, R', m.p. (decompn.), λ (detd. in 0.1N HCl), and type (L or DL) given]: H, CH(CO₂H)CH₂CHMe₂ (I), 278.degree., 270, L; H, CH(CO₂H)CHMeEt (II), 276-8.degree., 270, DL; H, CH(CO₂H)Et (III), 284-6.degree., 270, DL; CH₂(CO₂H), H (IV), 289-92.degree. (vacuum sealed capillary), 270, -; CH(CO₂H)Me, H (V), 222-5.degree., 209, DL; CH(CO₂H)2CH₂Ph, H (VI), 260-3.degree., 270, DL; H, CH(CO₂Et)CH₂CHMe₂ (VII), 119-20.degree. (no decompn.), -, -; CH₂(CO₂Et), H (VIII), 136-7.5.degree. (no decompn.), -, -. I-VI (white, amphoteric compds.) were prep'd. by condensation of 2-amino-4-chloro-6-methylpyrimidine or of 2-chloro-4amino-6-methylpyrimidine with equimolar amts. of amino acids in an aq. medium in the presence of small amts. of HCl, VII and VIII by passing dry HCl through an EtOH suspension (heated to 80.degree.) of I and II, resp., followed by treatment with aq. Na₂CO₃. III, IV, and V were purified by crystn. from H₂O, I, II, VI by dissolving in ammonia and pptg. by addn. of HCl to pH 6-7.degree., VII and VIII by dissolving in EtOH and pptg. with H₂O.

IT 92107-70-5, Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester


(prepn. of)

RN 92107-70-5 CAPLUS


CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2003 ACS
 AN 1961:54318 CAPLUS
 DN 55:54318
 OREF 55:10456f-g
 TI N-Pyrimidyl amino acids
 AU Roy-Burman, P.; Roy, Dolly; Sen, D.
 CS Univ. Colls. Sci. Technol., Calcutta
 SO Naturwissenschaften (1960), 47, 515-16
 DT Journal
 LA English
 AB 2-Amino-4-chloro-6-methylpyrimidine was condensed with equimolar amts. of amino acids in an aq. medium in the presence of small amts. of HCl. The 2-amino-4-chloro-6-methylpyrimidyl derivs. of the following were prep'd. and recrystd. from H₂O [m.p. (decompn.) given]: glycine, 298.degree.; DL-alanine, 290.degree.; DL-phenylalanine, 275.degree.; DL-valine, 287.degree.; DL-serine, 264.degree.. The ultraviolet absorption of these compds. showed a peak near 270 m.mu. (in 0.1N HCl).
 IT 89897-36-9, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-
 90198-25-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-
 92296-32-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-
 (prepn. of)
 RN 89897-36-9 CAPLUS
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAPLUS
 CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAPLUS
 CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)

09/907,273 (subgenus around elected species)



09/907,273 (subgenus around elected species)

=> d his

(FILE 'HOME' ENTERED AT 18:19:19 ON 21 FEB 2003)

FILE 'REGISTRY' ENTERED AT 18:19:25 ON 21 FEB 2003

L1 STRUCTURE UPLOADED
L2 21 S L1 SSS SAM
L3 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045
L4 STRUCTURE UPLOADED
L5 QUE L4 NOT L3
L6 50 S L5 SSS SAM
L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045
L8 STRUCTURE UPLOADED
L9 QUE L8 NOT L7
L10 50 S L9 SSS SAM
L11 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045
L12 STRUCTURE UPLOADED
L13 QUE L12 NOT L11
L14 3 S L13 SSS SAM
L15 88 S L13 SSS FUL

FILE 'CAPLUS' ENTERED AT 18:31:01 ON 21 FEB 2003


L16 40 S L15

FILE 'CAOLD' ENTERED AT 18:31:52 ON 21 FEB 2003


=> s 115
L17 12 L15

=> d 117 1-12 bib,hitstr


L17 ANSWER 1 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA62:5278h CAOLD
 TI pteridine derivs. - (IX) 2,6-diamino-4-hydroxypteridine and related dihydropteridines
 AU Stuart, Alexander; West, D. W.; Wood, H. C. S.
 IT 1140-88-1 1154-85-4 14699-57-1
 RN 1140-88-1 CAOLD
 CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI)
 (CA INDEX NAME)




RN 1154-85-4 CAOLD
 CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 14699-57-1 CAOLD
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




L17 ANSWER 2 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA61:15067a CAOLD
 TI effect of a number of N-pyrimidyl amino acids and of some of their 5-arylazo derivs. on the growth of certain microorganisms
 AU Roy-Burman, P.; Sen, D.
 IT 89465-54-3 89897-36-9 90198-25-7
 90198-46-2 90649-20-0 91253-20-2
 91253-21-3 91717-29-2 92296-32-7
 93432-76-9 93727-00-5 94093-95-5
 94264-54-7 95126-82-2 96063-58-0
 RN 89465-54-3 CAOLD
 CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 89897-36-9 CAOLD
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAOLD
 CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-46-2 CAOLD
 CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90649-20-0 CAOLD
 CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




RN 91253-20-2 CAOLD
 CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91253-21-3 CAOLD
 CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91717-29-2 CAOLD
 CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 92296-32-7 CAOLD
 CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)




RN 93432-76-9 CAOLD
 CN Benzoic acid, p-[(2-amino-4-[(carboxymethyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)



RN 93727-00-5 CAOLD
 CN Benzoic acid, p-[(2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAOLD
 CN Benzoic acid, p-[(2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)




RN 94264-54-7 CAOLD

CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)




RN 95126-82-2 CAOLD

CN Benzoic acid, p-[(2-amino-4-[(1-carboxyethyl)amino]-6-methyl-5-pyrimidinyl)azo]- (7CI) (CA INDEX NAME)




RN 96063-58-0 CAOLD

CN Hydrocinnamic acid, .alpha.-[(2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




L17 ANSWER 3 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA60:10681b CAOLD
 TI synthesis of some simple 2-substituted pyrimidines and 2,2'-bipyrimidines,
 and their anal. applications
 AU Bly, Donald D.; Mellon, M. G.
 IT 92385-16-5 93263-85-5
 RN 92385-16-5 CAOLD
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (7CI) (CA
 INDEX NAME)




●x HCl

RN 93263-85-5 CAOLD
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride
 (7CI) (CA INDEX NAME)




●x HCl


L17 ANSWER 4 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA60:1829g CAOLD
 TI potential antimetabolites - (VIII) acyclic amino acids from pyrimidines
 AU Shvachkin, Yu. P.; Syrtsova, L. A.
 IT 91194-85-3 91647-59-5 93002-46-1
 94823-79-7
 RN 91194-85-3 CAOLD
 CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)
 (CA INDEX NAME)



RN 91647-59-5 CAOLD
 CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, dimethyl ester
 (7CI) (CA INDEX NAME)




RN 93002-46-1 CAOLD
 CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)
 (CA INDEX NAME)




RN 94823-79-7 CAOLD


CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)




L17 ANSWER 5 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA60:1829e CAOLD
 TI potential antimetabolites - (VII) substituted N-(4-pyrimidyl)amino acids
 and their derivs.
 AU Shvachkin, Yu. P.; Berestenko, M. K.
 IT 91086-76-9 92286-86-7 92295-36-8
 92556-22-4 93537-11-2
 RN 91086-76-9 CAOLD
 CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA
 INDEX NAME)




RN 92286-86-7 CAOLD
 CN Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX
 NAME)



RN 92295-36-8 CAOLD
 CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA
 INDEX NAME)




RN 92556-22-4 CAOLD
 CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl
 ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAOLD


CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)
(CA INDEX NAME)




L17 ANSWER 6 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA59:11651c CAOLD
 TI structure of proteins - (VIII) prepn. of nitropyrimidylamino acids
 AU Scoffone, Ernesto.; Signor, A.; Biondi, L.
 IT 89854-39-7 90085-29-3 91978-49-3
 92295-36-8 92295-39-1 92347-91-6
 RN 89854-39-7 CAOLD
 CN Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 90085-29-3 CAOLD
 CN Serine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91978-49-3 CAOLD
 CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 92295-36-8 CAOLD
 CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)




RN 92295-39-1 CAOLD

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 92347-91-6 CAOLD


CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




L17 ANSWER 7 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA58:12559b CAOLD
TI synthesis of some N-pyrimidyl amino acids - (III)
AU Roy-Burman, P.; Sen, D.
IT 89465-54-3
RN 89465-54-3 CAOLD
CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




L17 ANSWER 8 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA58:8252h CAOLD
 TI N-(5-arylazo-4-pyrimidyl)amino acids as growth inhibitors of *Streptococcus faecalis*
 AU Roy-Burman, P.; Sen, D.
 IT 93432-76-9 93727-00-5 94093-95-5
 94264-54-7 95126-82-2 96063-58-0
 RN 93432-76-9 CAOLD
 CN Benzoic acid, p-[(2-amino-4-[(carboxymethyl)amino]-6-methyl-5-pyrimidinyl)azo]-(7CI) (CA INDEX NAME)




RN 93727-00-5 CAOLD
 CN Benzoic acid, p-[(2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl)azo]-(7CI) (CA INDEX NAME)



RN 94093-95-5 CAOLD
 CN Benzoic acid, p-[(2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl)azo]-(7CI) (CA INDEX NAME)




RN 94264-54-7 CAOLD
 CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]-(7CI) (CA INDEX NAME)




RN 95126-82-2 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxyethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 96063-58-0 CAOLD


CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)




L17 ANSWER 9 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA58:3425a CAOLD
 TI nucleophilic displacement reactions in the synthesis of
 N-(4-pyrimidyl)amino acids and their derivs.
 AU Shvachkin, Yu. P.; Berestenko, M. K.
 TI sulfanilamidopyrimidines - (II) 4-sulfanilamidopyrimidines and certain
 4,6-disubstituted pyrimidines
 AU Taft, William E.; Shepherd, R. G.
 IT 91086-76-9 91194-85-3 91647-59-5
 92295-36-8 92556-22-4 93002-46-1
 93537-11-2 94823-79-7
 RN 91086-76-9 CAOLD
 CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA
 INDEX NAME)




RN 91194-85-3 CAOLD
 CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)
 (CA INDEX NAME)




RN 91647-59-5 CAOLD
 CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, dimethyl ester
 (7CI) (CA INDEX NAME)




RN 92295-36-8 CAOLD
 CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)



RN 92556-22-4 CAOLD
 CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)




RN 93002-46-1 CAOLD
 CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAOLD

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)
(CA INDEX NAME)




RN 94823-79-7 CAOLD


CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)




L17 ANSWER 10 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA57:824b CAOLD
 TI synthesis of some N-pyrimidyl amino acids - (II)
 AU Roy-Burman, P.; Sen, D.; Guha, B. C.
 IT 90649-20-0 91253-20-2 91253-21-3
 92107-70-5
 RN 90649-20-0 CAOLD
 CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




RN 91253-20-2 CAOLD
 CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91253-21-3 CAOLD
 CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 92107-70-5 CAOLD
 CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)




L17 ANSWER 11 OF 12 CAOLD COPYRIGHT 2003 ACS
 AN CA55:10456g CAOLD
 TI structure of muta-aspergillic acid
 AU Nakamura, Seiji
 IT 89897-36-9 90198-25-7 90198-46-2
 91717-29-2 92296-32-7
 RN 89897-36-9 CAOLD
 CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAOLD
 CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-46-2 CAOLD
 CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 91717-29-2 CAOLD
 CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 92296-32-7 CAOLD
 CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA

09/907,273 (subgenus around elected species)


INDEX NAME)



L17 ANSWER 12 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA54:7712i CAOLD
TI hydropteridines - (V) 7,8-dihydro-6-hydroxy-4-pteridinecarboxylic acids
AU Clark, Jim; Layton, A. J.
IT 99988-33-7 100140-57-6
RN 99988-33-7 CAOLD
CN 4-Pyrimidinecarboxylic acid, 2-amino-6-[(carboxymethyl)amino]-5-nitro-,
diethyl ester (6CI) (CA INDEX NAME)



RN 100140-57-6 CAOLD
CN 4-Pyrimidinecarboxylic acid, 2,5-diamino-6-[(carboxymethyl)amino]-,
diethyl ester (6CI) (CA INDEX NAME)



09/907,273 (subgenus around elected species)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.84	369.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.04

STN INTERNATIONAL LOGOFF AT 18:32:33 ON 21 FEB 2003